VistaGen Therapeutics, Inc. (VTGN) - התחייבויות לטווח ארוך להון

Vistagen Therapeutics (VTGN) develops nasal sprays to combat phobias, capturing the psychopharmacology market. The long-term capital structure indicator on GURU.Markets displays financial stability, where 0.00 reflects the metric's baseline level. The company's revenues are based on sales through pharmacies and insurers. Development relies on the implementation of AI modules and robotic systems for molecule screening.

This metric assesses the stability of Vistagen Therapeutics (VTGN) through the ratio of long-term liabilities to its market value. By analyzing the share of long-term loans within the capital structure, an investor determines the issuer's degree of dependence on external borrowing. For Vistagen Therapeutics (VTGN), this is critical when financing the development of nasal sprays. A low debt load confirms financial flexibility when bringing drugs to market. This metric serves as an indicator of investment security.